Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-m

Major M&A deals this week include: The Descartes Systems buys Tai, KKR nabs Ci FLAVORS, Skimmer

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular

BioXcel Chapter 11 sends BTAI shares sharply lower as Teva becomes the stalking horse bidder for IGA

US stocks up, Dow gains 100 points, S&P 500 and NASDAQ also rise. Communication services up 1.1%

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-mark

Elastic NV (ESTC) stock rose 21.8% in pre-market trading after reporting strong Q1 results and raisi

BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximi

AI-driven biopharma firm BioXcel Therapeutics filed for Chapter 11 bankruptcy protection ​in the U.S

Ross Stores beats estimates with Q2 financial results, shares jump 9.1%. Other gainers include RFAI,

Flexsteel Industries Inc (FLXS) reported better-than-expected Q4 results, with shares jumping 9% in

Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's reg

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.49 per share versus the Zacks

Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session

Shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI - Get Free Report) have received an average recom

BigBear.ai (NYSE:BBAI), a specialized defense and security technology company providing mission-read

Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular sess

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's

Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's

BioXcel Therapeutics (BTAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligen

NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biop

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.54 per share versus the Zacks

FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date 

BioXcel Therapeutics (BTAI) possesses the right combination of the two key ingredients for a likely

BioXcel Therapeutics (NASDAQ: BTAI) outlined its commercial strategy and launch preparations for IGA

BioXcel Therapeutics, Inc. (BTAI) Discusses Commercial Launch Strategy and Market Opportunity for IG

Live event to be held on Thursday, April 23, at 2:00 p.m. ET  Company focused on advancing launch st

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob

DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Tra

PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the

sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of

HARTFORD, Conn., March 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that the United

Top Wall Street analysts changed outlook on top names. See full changes, upgrades, downgrades and in

NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nas

NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nas

BioXcel Therapeutics Inc. (NASDAQ: BTAI) shares are down on Friday.

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for tra

NVO: 7% | Novo Nordisk shares are trading higher after the FDA approved Wegovy for the treatment of